Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuroNet-PHL-C2 second international inter-group study in pediatric classical Hodgkin lymphoma
NL-OMON53041Phase 3Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Oct 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dacarbazine, cyclophosphamide, vincristine, prednisone, etoposide and 1 more in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Justus Liebig University Giessen. Primary endpoints: Event-free survival in ERA PET-negative TL-2 and TL-3 patients without radiotherapy, Comparative efficacy in ERA PET-positive TL-2 and TL-3 patients and 1 more. Started Oct 2016; status: completed.
02
Drugs
dacarbazinecyclophosphamidevincristineprednisoneetoposide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON53041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53041.